The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen ...

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and ...

Learn about prostate cancer, its early detection, symptoms, and treatment options. Know the importance of screenings and ...

A supplemental new drug application seeking expanded indication for darolutamide combined with androgen deprivation therapy ...

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug ...

It is one of the common treatment options for prostate cancer and can be used in various stages of the disease, either alone or in combination with other treatments like surgery or hormone therapy.

Radiopharmaceuticals have been used to treat patients with prostate cancer for decades, but experts say there is more to learn about these agents.

Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men With Biochemically Recurrent Prostate Cancer Aug. 22, 2024 — The anti-cancer drug olaparib may be effective in ...

September 18, 2024 Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making. September 18, 2024 Physician Perspectives on the ...